Ganglioside GM2 Mixture (bovine brain) (ammonium salt)
Ganglioside GM2 Mixture (bovine brain) (ammonium salt) structure
|
Common Name | Ganglioside GM2 Mixture (bovine brain) (ammonium salt) | ||
|---|---|---|---|---|
| CAS Number | 19600-01-2 | Molecular Weight | 1384.682 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 1417.9±65.0 °C at 760 mmHg | |
| Molecular Formula | C67H121N3O26 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 811.3±34.3 °C | |
| Name | ganglioside GM2 |
|---|---|
| Synonym | More Synonyms |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 1417.9±65.0 °C at 760 mmHg |
| Molecular Formula | C67H121N3O26 |
| Molecular Weight | 1384.682 |
| Flash Point | 811.3±34.3 °C |
| Exact Mass | 1383.823853 |
| LogP | 10.77 |
| Vapour Pressure | 0.0±0.6 mmHg at 25°C |
| Index of Refraction | 1.577 |
| Storage condition | -20°C |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
|
Altered levels of α-synuclein and sphingolipids in Batten disease lymphoblast cells.
Gene 539(2) , 181-5, (2014) Batten disease (juvenile neuronal ceroid lipofuscinosis) is a neurodegenerative disorder characterized by blindness, seizures, cognitive decline, and early death due to the inherited mutation of the C... |
|
|
Ganglioside-embedding small bicelles for probing membrane-landing processes of intrinsically disordered proteins.
Chem. Commun. (Camb.) 49(12) , 1235-7, (2013) We successfully displayed a series of gangliosides on small bicelles with a uniform confined size, offering nanoscale standardized membrane mimics for spectroscopic characterization of weak encounter ... |
|
|
Use of carbohydrate-conjugated nanoparticles for an integrated approach to functional imaging of glycans and understanding of their molecular mechanisms.
Curr. Pharm. Biotechnol. 13(14) , 2612-6, (2012) Functional analysis of carbohydrates is needed to understand the initial interface between membranes and the outer world. For this analysis we need individual protocols such as a method to modify the ... |
| (2R,3S,4E)-3-Hydroxy-2-(stearoylamino)-4-octadecen-1-yl 2-acetamido-2-deoxy-β-L-galactopyranosyl-(1->4)-[(6S)-5-acetamido-3,5-dideoxy-6-[(1S,2S)-1,2,3-trihydroxypropyl]-β-D-threo-hex-2-ulopyrano nosyl-(2->3)]-β-L-galactopyranosyl-(1->4)-β-L-glucopyranoside |
| MFCD00131137 |
| Octadecanamide, N-[(1R,2S,3E)-1-[[[O-2-(acetylamino)-2-deoxy-β-L-galactopyranosyl-(1->4)-O-[5-(acetylamino)-3,5-dideoxy-L-glycero-α-L-galacto-2-nonulopyranonosyl-(2->;3)]-O-β-L-galactopyranos yl-(1->4)-β-L-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]- |